Gottipamula S.,Stempeutics Research Pvt. Ltd Shirdi Sai Baba Cancer Hospital Manipal India |
Muttigi M.S.,Stempeutics Research Pvt. Ltd Shirdi Sai Baba Cancer Hospital Manipal India |
Chaansa S.,Stempeutics Research Pvt. Ltd Shirdi Sai Baba Cancer Hospital Manipal India |
Ashwin K.M.,Stempeutics Research Pvt. Ltd Shirdi Sai Baba Cancer Hospital Manipal India |
And 5 more authors.
Journal of Tissue Engineering and Regenerative Medicine | Year: 2013
The regenerative potential of mesenchymal stromal or stem cells (MSCs) has generated tremendous interest for treating various degenerative diseases. Regulatory preference is to use a culture medium that is devoid of bovine components for stem cell expansion intended for therapeutic applications. However, a clear choice an alternative to fetal bovine serum (FBS) has not yet emerged. We have screened five different commercially available serum-free media (SFM) for their ability to support the growth and expansion of pre-isolated undifferentiated bone marrow-derived MSCs (BM-MSCs) and compared the results with cells grown in standard FBS-containing medium as control. In addition, based on initial screening results, BD Mosaic™ Mesenchymal Stem Cell Serum-free (BD-SFM) medium was evaluated in large-scale cultures for the performance and culture characteristics of BM-MSCs. Of the five different serum-free media, BD-SFM enhanced BM-MSCs growth and expansion in Cell STACK (CS), but the cell yield per CS-10 was less when compared to the control medium. The characteristics of MSCs were measured in terms of population doubling time (PDT), cell yield and expression of MSC-specific markers. Significant differences were observed between BD-SFM and control medium in terms of population doublings (PDs), cell yield, CFU-F and morphological features, whereas surface phenotype and differentiation potentials were comparable. The BD-SFM-cultured MSCs were also found to retain the differentiation potential, immune-privileged status and immunosuppressive properties inherent to MSCs. Our results suggest that BD-SFM supports large-scale expansion of BM-MSCs for therapeutic use. © 2013 John Wiley & Sons, Ltd.